The natural flow motion for pumps
The Wavera® Technology
Essential yet invisible, pumps are everywhere
Pumps consume 10% of worldwide electricity production — as much as the digital industry with its data centres and terminals combined — and represent up to 80% of the energy costs of processes in industries such as water treatment and food and beverage production. Furthermore, 10% of the world’s pumps are renewed every year.
The Wavera® undulating membrane can be adapted to all types of pumps in response to the market needs: costs, consumption, size and durability.
The Wavera® technology consists in using a linear motor to move a flexible membrane whose undulating movement, like the one of a fish’s fin, propels the fluid from the membrane’s excited side (upstream) to its free side (downstream).
Up to 30% power saving
Lighter and smaller
Optimal on several operating points
Continuous flow (or possibility of pulsation)
Very rapid response time (12 milliseconds)
40 times less fluid shearing
High hydraulic/mechanical efficiency (80%)
Robust (no breakable parts: shaft, bearings, valve...)
Lower maintenance and power consumption costs
Unique in today's market
80 Million of cars (2015)
USD 3,8 Billion / year (2015)
USD 3,6 Billion / year
Dying out of buildings
USD 2 Billion / year (2015)
Food & beverages
USD 2,9 Billion / year (2015)
USD 5,4 Billion / year (2015)
50 Million pumps / year (2015)
80 000 fills / day
USD 2,4 Billion / year (2015)
USD 6,2 Billion / year (2015)
USD 2,9 Billion / year (2015)
AMS R&D was created by Erik Guillemin (Founding President) in order to develop the possibilities of the Wavera® undulating membrane fluid propulsion technology invented by Jean-Baptiste Drevet (engineer from the Arts et Métiers), for which AMS R&D owns all patents and technological expertise.
Each Wavera® pump comprises three innovative parts :
the membrane, the heart of the Wavera® technology, which propels the fluid;
the linear motor, whose up-and-down motion gives the membrane its undulation;
the electronics, which control the linear motor and thereby, the pump.
The application fields targeted in the short term by AMS R&D cover the medium and low pressures, where are present different technologies, such as centrifugal, conventional membrane or peristaltic pumps. These pumps are used in all industrial sectors, and represent a global park of several billion units, of which hundreds of millions are renewed annually.
AMS R&D is licensing its Wavera® technology to pump manufacturers to expand this energy efficient system as widely as possible.
AMS R&D is currently partnering with leading leaders in :
CorWave : MedTech Start-up
Using the undulating membrane technology, CorWave LVAD can restore blood flow while preserving high fidelity pulsatility, unlike continuous-flow rotary pumps that provide limited and artificial pulsatility. It works similarly to the native heart, faithfully recreating the ejection (systole) and filling (diastole) phases without exposing the blood to the damage caused by current commercially available LVADs.
At the heart of CorWave’s products, CorWave LVAD and Nemo, is a disruptive and patented pumping technology: the undulating membrane. The membrane is the result of over twenty years of research and development by AMS R&D SAS, and is capable of mimicking the native heart. This disruptive technology radically differentiates CorWave products from commercially available rotary pump LVADs and allows CorWave LVAD and Nemo to deliver a unique physiological blood flow.
The undulating membrane is a biomimetic technology inspired by the undulating motion of marine animals. This movement provides an efficient way for animals to move fluids, propelling them through the water. In CorWave pumps, a polymer membrane mimics a similar interaction, albeit in reverse: the membrane is fixed and the fluid (blood) is moved.
After more than 20 years of research, this technology is protected by several patent families.
A standard implantation procedure
The CorWave LVAD pump can be implanted via the standard surgical procedures performed by surgeons today, the sternotomy and/or thoracotomy.
Thanks to its compact design, it will be implantable in the intrapericardial cavity and will be compatible with less invasive procedures.
A true relay for the heart
A left ventricular assist device (LVAD) is an implantable pump connected to the heart, linking the apex of the left ventricle to the ascending aorta.
LVADs are intended to treat patients with advanced heart failure. They help or take over the function of the heart that has become too weak to pump blood effectively.
LVADs restore enough blood flow to suppress the symptoms of heart failure in these critically ill patients.
LVADs are implanted surgically, under general anesthesia, by opening the sternum (sternotomy) or by a less invasive combined procedure (mini-sternotomy and/or thoracotomy). Once implanted, power and controls for the device are provided via an external cable running through the patient's abdomen, connecting the pump to a controller and two batteries.
Create a new standard of care for a large spectrum of heart failure patients by introducing breakthrough implantable circulatory support solutions that restore a normal life with minimal side effects.
more information on :
Press contact :
Brigitte Baranès Conseil
24 rue de l'Est
Head quarter :
2, rue Suzanne Ruelle